Table 1.
The clinical information description of all patients
| Inflammatory activity | Fibrosis stage | |||||
|---|---|---|---|---|---|---|
| G0‐1 (n = 239) | G2‐3 (n = 84) | P value | S0‐1 (n = 252) | S2‐4 (n = 70) | P value | |
| Age (y) | 34.0 (27.0‐41.0) | 39.0 (30.0‐44.3) | >.05 | 35.0 (27.0‐41.0) | 39.0 (30.0‐43.8) | >.05 |
| ALT (IU/L) | 33.0 (21.0‐46.0) | 46.0 (30.0‐64.0) | <.05 | 35.0 (23.0‐49.0) | 46.0 (25.0‐68.5) | <.05 |
| AST (IU/L) | 28.0 (23.0‐34.5) | 35.0 (28.0‐47.0) | >.05 | 28.5 (23.0‐36.0) | 35.0 (27.5‐48.5) | >.05 |
| GGT (IU/L) | 16.0 (12.0‐24.0) | 23.0 (14.0‐36.0) | <.05 | 16.0 (12.0‐24.0) | 23.0 (14.0‐36.5) | <.05 |
| HBV DNA (log10 copies/mL) | 4.8 (3.5‐7.6) | 5.4 (3.8‐6.9) | >.05 | 4.9 (3.6‐7.7) | 5.3 (3.7‐6.6) | >.05 |
| WBC (109/L) | 5.4 (4.6‐6.7) | 5.3 (4.3‐6.4) | >.05 | 5.4 (4.7‐6.7) | 5.4 (4.4‐6.3) | >.05 |
| PLT (109/L) | 163 (130‐196) | 122 (97‐167) | <.05 | 162 (129‐195) | 120 (100‐163) | <.05 |
| Monocytes (%) | 6.4 (5.2‐7.5) | 6.8 (5.8‐8.0) | <.05 | 6.5 (5.3‐7.6) | 6.6 (5.5‐9.0) | >.05 |
| RDWCV | 13.0 (12.5‐13.7) | 13.1 (12.7‐13.8) | >.05 | 13.0 (12.5‐13.6) | 13.2 (12.6‐13.9) | >.05 |
| PT(s) | 11.6 (11.0‐12.1) | 11.7 (11.1‐12.4) | >.05 | 11.6 (11.0‐12.1) | 11.8 (11.2‐12.4) | >.05 |
| Inflammation grade (G0/G1/G2/G3) | 4 (1.2%)/235 (71.8%)/69 (21.4%)/18 (5.6%) | |||||
| Fibrosis stage (S0/S1/S2/S3/S4) | 35 (10.8%)/217 (67.2%)/39 (12.1%)/23 (7.1%)/8 (2.5%) | |||||
| HBeAg positive (%) | 133 (41.2%) | |||||
| Male (%) /Female (%) | 213 (65.3%)/110 (34.1%) | |||||
Data were expressed as median (quartile range) and compared with Kruskal‐Wallis H test, P < .05 considered statistical significance.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transpeptidase; PLT, platelet count; WBC, white‐blood cell; PT, prothrombin time; RDW, red cell distribution width.